These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
528 related articles for article (PubMed ID: 30991414)
1. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease. Nakanishi T; Kimura T; Kuragano T Contrib Nephrol; 2019; 198():124-134. PubMed ID: 30991414 [TBL] [Abstract][Full Text] [Related]
2. Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease. Kimura T; Kuragano T; Yamamoto K; Nanami M; Hasuike Y; Nakanishi T Int J Hematol; 2019 Jan; 109(1):59-69. PubMed ID: 30232784 [TBL] [Abstract][Full Text] [Related]
3. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Landau D; London L; Bandach I; Segev Y PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538 [TBL] [Abstract][Full Text] [Related]
4. Inappropriately low reticulocytosis in severe malarial anemia correlates with suppression in the development of late erythroid precursors. Chang KH; Tam M; Stevenson MM Blood; 2004 May; 103(10):3727-35. PubMed ID: 14739226 [TBL] [Abstract][Full Text] [Related]
5. Hepcidin in chronic kidney disease anemia. Santos-Silva A; Ribeiro S; Reis F; Belo L Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815 [TBL] [Abstract][Full Text] [Related]
6. Malarial anaemia: mechanisms and implications of insufficient erythropoiesis during blood-stage malaria. Chang KH; Stevenson MM Int J Parasitol; 2004 Dec; 34(13-14):1501-16. PubMed ID: 15582527 [TBL] [Abstract][Full Text] [Related]
7. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Malyszko J; Malyszko JS; Matuszkiewicz-Rowinska J Expert Opin Ther Targets; 2019 May; 23(5):407-421. PubMed ID: 30907175 [TBL] [Abstract][Full Text] [Related]
8. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease. Olivari V; Di Modica SM; Lidonnici MR; Aghajan M; Cordero-Sanchez C; Tanzi E; Pettinato M; Pagani A; Tiboni F; Silvestri L; Guo S; Ferrari G; Nai A Kidney Int; 2023 Jul; 104(1):61-73. PubMed ID: 36990212 [TBL] [Abstract][Full Text] [Related]
9. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821 [TBL] [Abstract][Full Text] [Related]
10. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S; Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289 [TBL] [Abstract][Full Text] [Related]
11. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. Weir MR Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923 [TBL] [Abstract][Full Text] [Related]
12. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Sun CC; Vaja V; Chen S; Theurl I; Stepanek A; Brown DE; Cappellini MD; Weiss G; Hong CC; Lin HY; Babitt JL Nephrol Dial Transplant; 2013 Jul; 28(7):1733-43. PubMed ID: 23345622 [TBL] [Abstract][Full Text] [Related]
13. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. Menon MP; Karur V; Bogacheva O; Bogachev O; Cuetara B; Wojchowski DM J Clin Invest; 2006 Mar; 116(3):683-94. PubMed ID: 16511603 [TBL] [Abstract][Full Text] [Related]
14. Flow Cytometry (FCM) Analysis and Fluorescence-Activated Cell Sorting (FACS) of Erythroid Cells. An X; Chen L Methods Mol Biol; 2018; 1698():153-174. PubMed ID: 29076089 [TBL] [Abstract][Full Text] [Related]
15. Iron Metabolism in Chronic Kidney Disease Patients. Honda H; Hosaka N; Ganz T; Shibata T Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401 [TBL] [Abstract][Full Text] [Related]
17. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study . Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472 [TBL] [Abstract][Full Text] [Related]
18. Low level arsenite exposures suppress the development of bone marrow erythroid progenitors and result in anemia in adult male mice. Medina S; Xu H; Wang SC; Lauer FT; Liu KJ; Burchiel SW Toxicol Lett; 2017 May; 273():106-111. PubMed ID: 28359802 [TBL] [Abstract][Full Text] [Related]
19. Abnormal erythroid differentiation in neonatal bcl-6-deficient mice. Asari S; Sakamoto A; Okada S; Ohkubo Y; Arima M; Hatano M; Kuroda Y; Tokuhisa T Exp Hematol; 2005 Jan; 33(1):26-34. PubMed ID: 15661395 [TBL] [Abstract][Full Text] [Related]
20. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]